These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. A further point about statins... Gilden D GMHC Treat Issues; 1998 Jun; 12(6):8. PubMed ID: 11365725 [TBL] [Abstract][Full Text] [Related]
6. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Fichtenbaum CJ; Gerber JG Clin Pharmacokinet; 2002; 41(14):1195-211. PubMed ID: 12405866 [TBL] [Abstract][Full Text] [Related]
8. Protease inhibitor drug interactions. Rose E; Romeyn M BETA; 1997 Sep; ():29-38. PubMed ID: 11364696 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and antiviral activities of the major metabolites of the HIV protease inhibitor ABT-378 (Lopinavir). Sham HL; Betebenner DA; Herrin T; Kumar G; Saldivar A; Vasavanonda S; Molla A; Kempf DJ; Plattner JJ; Norbeck DW Bioorg Med Chem Lett; 2001 Jun; 11(11):1351-3. PubMed ID: 11378352 [TBL] [Abstract][Full Text] [Related]
11. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Barry M; Gibbons S; Back D; Mulcahy F Clin Pharmacokinet; 1997 Mar; 32(3):194-209. PubMed ID: 9084959 [TBL] [Abstract][Full Text] [Related]
12. Protease inhibitor plasma concentrations in HIV antiretroviral therapy. Justesen US Dan Med Bull; 2008 Nov; 55(4):165-85. PubMed ID: 19232158 [TBL] [Abstract][Full Text] [Related]
13. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Hsu A; Granneman GR; Bertz RJ Clin Pharmacokinet; 1998 Oct; 35(4):275-91. PubMed ID: 9812178 [TBL] [Abstract][Full Text] [Related]
14. Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Wire MB; Shelton MJ; Studenberg S Clin Pharmacokinet; 2006; 45(2):137-68. PubMed ID: 16485915 [TBL] [Abstract][Full Text] [Related]